A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Deoxycytidine
  • Organoplatinum Compounds
  • Pancreatectomy
  • Pancreatic Neoplasms

abstract

  • This study met its endpoint and provided a signal suggesting that exploration of neoadjuvant systemic therapy is worthy of further investigation in resectable pancreas adenocarcinoma. Improved patient selection and more active systemic regimens are key. Clinical trials identification: NCT00536874.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4520299

Digital Object Identifier (DOI)

  • 10.1097/SLA.0000000000000251

PubMed ID

  • 24901360

Additional Document Info

start page

  • 142

end page

  • 8

volume

  • 260

number

  • 1